Displaying 1 - 2 of 2
| Active Ingredient | EFAVIRENZ |
| Therapeutic Class | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIB (NNRTI) |
| Indications |
In combination with other antiretrovirals for the treatment of HIV-1 infection. Efavirenz usually is used in HIV nonnucleoside reverse transcriptase inhibitor-based (NNRTI-based) regimens that includ More ... |
| Caution | Psychiatric disorders, rash, increases in liver enzymes. |
| Dose Range |
Adult: 600mg once daily on an empty stomach preferably at bedtime. Pediatric: 3 years and older and weighing between 10-40kg: 200mg-600mg once daily . |
| Drug Interactions | Efavirenz induces CYP3A and 2B6, and may alter plasma concentrations of drugs metabolized by these enzymes. |
| Pregnancy | Efavirenz may cause fetal harm if administered during the first trimester of pre More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | EFAVIRENZ | EMTRICITABINE | TENOFOVIR |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | HIV infection |
| Caution | Lactic acidosis and severe hep atomegaly with steatosis, including fatal cases, have been rep orted with the use of nucleoside analogues in combination with other antiretrovirals. |
| Dose Range | One tablet once daily on an empty stomach; not recommended for pediatric patients younger than 18 years. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |